logo
explain how to read the page

The above diagram shows the color scheme of the layout in the main result page. The parent entities and officers are those entities, including individual and legal persons, have significant controls over the company in focus. The offspring entities and appointments are those entities that the company in focus can influence on.

Clicking the links on parent entities or officers, and offspring entities or managed companies will put them in focus and show upstream or downstream connections. In general, ascendant entities can be found by moving toward upstream, and descendant entities are by toward downstream. In this way, progenitor entities such as grandparent companies (parents of parent), sibling companies (children of parent), partner companies (parents of child), and progeny entities such as grandchild companies (children of child) can be found easily.

Parent entities and officers 4
  • 1
    Smit, Willem Anton, Mr.
    Born in May 1975
    Individual (33 offsprings)
    Officer
    2022-08-01 ~ now
    OF - Director → CIF 0
  • 2
    Mr. Karan Bagaria
    Born in July 1984
    Individual (1 offspring)
    Person with significant control
    2022-08-01 ~ 2024-03-24
    PE - Right to appoint or remove directorsCIF 0
  • 3
    Mr. Anurag Bagaria
    Born in November 1976
    Individual (1 offspring)
    Person with significant control
    2022-08-01 ~ now
    PE - Right to appoint or remove directorsCIF 0
  • 4
    AMICORP (UK) SECRETARIES LIMITED
    04194501
    3rd Floor, 5 Lloyds Avenue, London, United Kingdom
    Active Corporate (20 parents, 349 offsprings)
    Officer
    2022-08-01 ~ now
    OF - Secretary → CIF 0
parent relation
Company in focus

KEMWELL BIOPHARMA UK LTD

Period: 2022-08-01 ~ now
Company number: 14267657
Registered name
KEMWELL BIOPHARMA UK LTD - now
Standard Industrial Classification
72110 - Research And Experimental Development On Biotechnology
Brief company account
Fixed Assets - Investments
12,858,336 GBP2025-03-31
6,552,559 GBP2024-03-31
Debtors
19,325 GBP2025-03-31
27,090 GBP2024-03-31
Cash at bank and in hand
39,366 GBP2025-03-31
235,567 GBP2024-03-31
Current Assets
58,691 GBP2025-03-31
262,657 GBP2024-03-31
Net Current Assets/Liabilities
38,057 GBP2025-03-31
251,266 GBP2024-03-31
Total Assets Less Current Liabilities
12,896,393 GBP2025-03-31
6,803,825 GBP2024-03-31
Equity
Called up share capital
13,139,317 GBP2025-03-31
6,947,882 GBP2024-03-31
Retained earnings (accumulated losses)
-242,924 GBP2025-03-31
-144,057 GBP2024-03-31
Equity
12,896,393 GBP2025-03-31
6,803,825 GBP2024-03-31
Average Number of Employees
02024-04-01 ~ 2025-03-31
02023-04-01 ~ 2024-03-31
Investments in group undertakings and participating interests
12,858,336 GBP2025-03-31
6,552,559 GBP2024-03-31
Trade Debtors/Trade Receivables
Current
19,325 GBP2025-03-31
27,090 GBP2024-03-31
Bank Borrowings/Overdrafts
Current
0 GBP2025-03-31
141 GBP2024-03-31
Amounts owed to group undertakings
Current
20,634 GBP2025-03-31
11,250 GBP2024-03-31
Creditors
Current
20,634 GBP2025-03-31
11,391 GBP2024-03-31

  • KEMWELL BIOPHARMA UK LTD
    Info
    Registered number 14267657
    3rd Floor, 5 Lloyds Avenue, London EC3N 3AE
    PRIVATE LIMITED COMPANY incorporated on 2022-08-01 (3 years 10 months). The status of the company number is Active.
    The last date of confirmation statement was made at 2026-02-07
    CIF 0
child relation
Offspring entities and appointments 0
  • Not found in our database.

The content of this website is protected by AgonGuard.

© 2022- Polylogarithmic Technology Ltd (Registered in England and Wales No. 14256313). All rights reserved.

Contains public sector information retrieved at 22 April 2026 and licensed under the Open Government Licence v3.0.